The Weekly Recap 5/22/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Activ Surgical

Partnered with Medical Dynamics to be the company’s exclusive distribution partner in Belgium, the Netherlands, and Luxembourg for ActivSight™. ActivSight Intelligent Light is the first and only modular form-factor with multimodal Advanced Visualization, allowing surgeons to augment their senses using augmented reality overlays.

Adagio Medical

Submitted PMA application to the FDA for its vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease. The submission is supported by the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients and demonstrated 97.4% acute clinical success, 84.3% freedom from ICD shock at six months, low major adverse event rates, and a 78% reduction or elimination of anti-arrhythmic drug use.

Aevice Health

Announced a new collaboration with Cedars-Sinai Medical Center to launch a pediatric at-home asthma monitoring program powered by its smart wearable stethoscope. The AeviceMD is an at-home monitoring device designed to track early signs of asthma and provide clinicians with continuous or on-demand remote monitoring of lung sounds.

Arsenal Medical

Received FDA IDE approval to initiate RADIANT, a pivotal trial evaluating NeoCast™. NeoCast is a novel liquid embolic under development that is designed to achieve pain-free, predictable distal penetration of the middle meningeal artery. 

Asabys Partners

Announced the launch of Asabys Innvierte Tech Transfer, a new fund backed by the Ministry of Science, Innovation, and Universities, through CDTI, and the EIF, with a joint commitment of €74.7M. With a target size of up to €120M, the fund will support the creation and growth of breakthrough companies in biotechnology and medical technologies, with a strong focus on technology transfer from universities, hospitals, and research centers.

Cagent Vascular

Announced the successful completion of the first human-use cases with the Serranator^Ⓡ SONIC Intravascular Lithotripsy System and the closing of a $41M Series D financing round. The round, co-led by U.S. Venture Partners (USVP) and Astoria Health Investors, funds the global REMODEL II pivotal trial and commercial launch of the SONIC IVL System.

Elixir Medical

Announced four-year results from the BIOADAPTOR randomized controlled trial comparing its DynamX coronary bioadaptor system to the Medtronic Resolute Onyx DES, highlighting durable clinical outcomes with DynamX. Investigators reported no new target lesion failure or cardiovascular death events between years three and four, while the system maintained a very low plateauing rate of adverse events compared to the continued annual increase seen with drug-eluting stents.

Endologix

Acquired the Pounce™ Thrombectomy System from Surmodics, closing the deal on May 18, 2026. Pounce, a clinically differentiated mechanical thrombectomy system for peripheral arterial clots, enables the company to support a broader continuum of care for patients with peripheral vascular disease and complements the company’s existing vascular intervention portfolio for the physicians who treat them.

Galvanize Therapeutics

Received FDA 510(k) clearance for the Aliya^Ⓡ EX Generator, expanding the Aliya PEF portfolio by enabling treatment across a broader range of lesion sizes with an ablation zone up to seven times larger. Aliya EX maintains the core attributes of the platform’s pulsed electric field technology, including predictable non-thermal ablation, a favorable safety profile, compatibility with existing workflows and therapies, and potential immune activation.

Garland Surgical

Closed a €3.5M Seed funding round consisting of €2.1M in equity financing and up to €1.4M in non-dilutive grant funding from Malta Enterprise. The financing will support product development, regulatory preparation, early clinical activities, and completion of the final design and verification of the TriActiv Hip system ahead of Europe and U.S. regulatory submissions.

HistoSonics

Received TFDA approval for its Edison^Ⓡ System, representing a significant milestone in the company’s global expansion efforts and continued growth across Asia. Currently, the Edison System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using histotripsy, a non-thermal, mechanical process of focused ultrasound.

Joint Preservation Innovations

Received the 2026 AANA Lightbulb Award in the Innovation Battle for new companies for its Articulator™ Arthroscopic Bur, the first and only FDA-cleared articulating rotary cutting instrument and recipient of FDA BDD. The Articulator features real-time surgeon-controlled articulation and more than 600% greater cutting surface area than conventional straight burs, enabling precise bone resection in challenging anatomical spaces during hip, shoulder, knee, and ankle procedures.

Keyron Medical Technology

Published that its ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomized preclinical study in the gastroenterology journal Gut. ForePass is designed to be incision-free, fully reversible, and deployable through a short outpatient endoscopic procedure.

Lauxera Capital Partners

Closed its Lauxera Growth II fund at €520M, surpassing its €500M hard cap and nearly doubling the size of the firm’s debut fund. Lauxera Growth II plans to deploy capital across 12 to 15 companies as both minority and majority investors, with individual investments of €20M to €50M.

Meduloc

Completed its first-in-human case using the meduloc system in a 21-year-old female with a comminuted, displaced fracture of the second metacarpal caused by a penetrating nail injury. The procedure achieved stable fixation with rotational and length stability while preserving the MCP joint through a minimally invasive antegrade approach, with six-week follow-up imaging showing stable implant positioning and strong healing progression.

Mosie Baby

Acquired by Premier Sperm Bank. The company has developed the first FDA-cleared at-home intravaginal insemination kit, which features a unique slit opening and has helped over 100,000 people on their path to parenthood. 

Neurosoft Bioelectronics

Closed a $7.5M oversubscribed seed funding round led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, Connecticut Innovations, and others. The funding will support the advancement of its minimally invasive neural interface technology toward U.S. commercialization, while expanding the large-scale neural datasets needed to build next-generation cortical foundation models.

Sensome

Announced positive results from its first-in-human INSPECT study evaluating its microsensor technology integrated into a smart stylet for bronchoscopic lung biopsy. The study showed that the company’s tumor detection technology safely and accurately identified and differentiated between cancerous tissue and healthy tissue.

Sentante

Received CE mark approval for its multi-domain robotic platform technology. The device is designed to support endovascular procedures with enhanced precision and control, addressing critical needs in and redefining endovascular intervention procedures.

Terapet

Announced partnership with Leo Cancer Care to help bring real-time in vivo treatment verification to upright particle therapy. By integrating upright treatment delivery with advanced PET-based verification technology, this collaboration aims to integrate treatment planning, delivery, and verification into a single streamlined workflow alongside RaySearch Laboratories, supporting the future of adaptive and data-driven particle therapy.

Tulyp Medical

Appointed LSI Alumni Steve Motes as CEO. Motes brings more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies, holding leadership roles at Draeger, Medtronic(formerly Somanetics), Edwards Lifesciences, and Abbott. 

VahatiCor

Appointed Harry Rowland, PhD, as CEO. Dr. Rowland brings experience leading cardiovascular medical technology companies through clinical development, regulatory approval, and commercialization, including serving as CEO and President of Endotronix, where he raised more than $150M and expanded to over 150 employees. 

Vitestro

Appointed LSI Alumni Eliane Schutte to its Board of Directors as a non-executive, independent director. Schutte brings more than 25 years of global leadership experience across medtech and biotech, with deep expertise in product development, clinical strategy, quality assurance, regulatory affairs, and commercialization.

Vortex Imaging

Closed a $12M financing round, supported by existing and new investors, including 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, and PhiFund Ventures, to support development, regulatory clearance, and commercialization of the company’s computational ultrasound system. The company also appointed LSI Alumni Ori Hadomi as Chairman of the Board, bringing significant experience in guiding transformative medical technologies from development to global commercialization.

Xeltis

Appointed Elmar Horn as Vice President of Commercial. Horn brings over 20 years of international medtech experience, previously serving as Sales Director for Peripheral Medical Devices DACH at Philips, where he led the peripheral vascular medical device business across Germany, Austria, and Switzerland.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.